Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction-Pipeline Review, H1 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.
Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)
Key Topics Covered in the Report:
Nicotine Addiction Market Research Report
Nicotine Addiction Market Trends
Key Players in Nicotine Addiction Therapeutics
Global Nicotine Addiction Overview
Global Nicotine Addiction Market Forecast
Global Nicotine Addiction Future Projections
Global Nicotine Addiction Competition Analysis
Global Nicotine Addiction Customer Preference
Global Nicotine Addiction Competitive Landscape
For more coverage click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/nicotine-addiction/88364-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
